Key stats
About CI BIO-REVOLUTION INDEX ETF COM UNIT
Expense ratio
0.72%
Home page
Inception date
Feb 24, 2022
Solactive Global Genomics Immunology and Medical Revolution CAD Hedged Index NTR - CAD - Benchmark TR Net
The fund is passively managed to provide global exposure to companies that are involved in the biotechnology and genomics industry, which encompasses healthcare products specializing in medicines, vaccines and consumer healthcare, gene editing, genomic sequencing, genetic diagnostics, genetic medicine and therapies, life science tools and analytical instruments for genetic variation and function research, treatment of various types of cancer and related complications, and vaccines to prevent infectious diseases. The index uses a proprietary natural language processing (NLP) algorithm to screen publicly available information and score companies for thematic exposure. Companies with no relevant exposure are screened out and the 50 highest-scoring companies are selected. The resulting portfolio is weighted equally, with security weights scaled by their ranking score. The index is rebalanced monthly.
Classification
Returns
| 1 month | 3 months | Year to date | 1 year | 3 years | 5 years | |
|---|---|---|---|---|---|---|
| Price performance | — | — | — | — | — | — |
| NAV total return | — | — | — | — | — | — |
What's in the fund
Exposure type
Health Technology
Stocks97.58%
Health Technology95.82%
Health Services1.76%
Bonds, Cash & Other2.42%
Miscellaneous2.33%
Cash0.10%
Stock breakdown by region
North America84.82%
Europe10.92%
Asia4.26%
Latin America0.00%
Africa0.00%
Middle East0.00%
Oceania0.00%
Top 10 holdings
Dividends
Dividend payout history